Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorCetin, Abdurrahman
dc.contributor.authorBiltekin, Burcu
dc.contributor.authorDegirmencioglu, Sevgin
dc.date.accessioned2020-12-02T18:01:42Z
dc.date.available2020-12-02T18:01:42Z
dc.date.issued2019
dc.identifier.issn1878-8750
dc.identifier.issn1878-8769
dc.identifier.urihttps://doi.org/10.1016/j.wneu.2019.08.257
dc.identifier.urihttp://hdl.handle.net/11446/3699
dc.descriptionCetin, Abdurrahman/0000-0002-5246-7652en_US
dc.descriptionWOS: 000496966300010en_US
dc.descriptionPubMed: 31518741en_US
dc.description.abstractBACKGROUND: the anticarcinogenic effect of ellagic acid (EA), a natural phenol of fruits and vegetables, has been investigated in several types of tumors. the combined effect of EA with bevacizumab (BEV), a common drug used in treatment of recurrent glioma, on glioblastoma has not been reported. This study observed the combined effect of EA with BEV on the expression profile of the C6 glioma cell line. METHODS: Rat C6 glioma cells were treated with EA at 100 mu mol/L concentration in combination with BEV at 100 ng/mL concentration for 24, 48, and 72 hours. Cell proliferation was detected by 5-bromo-2'-deoxyuridine immunohistochemistry, and p53 and caspase-3 protein levels were determined by immunohistochemistry and assessed by the H-Score. Expression profiles for P-glycoprotein (MDR1), O-6-methylguanine DNA methyltransferase (MGMT), caspase-3, and p53 related proteins were detected by reverse transcriptase polymerase chain reaction after EA treatment with or without BEV. RESULTS: EA combined with BEV conspicuously reduced the cell viability of C6 glioma cells for all incubation times. EA significantly downregulated expression of MGMT regardless of combination with BEV even in the early hours after treatment. Combined EA and BEV reduced MDR1 expression only at 72 hours. EA affected the apoptotic proteins of p53 and caspase-3 at protein level in a time-dependent manner, but not at gene level. CONCLUSIONS: This study suggests successful antiproliferative efficacy of EA combined with BEV, probably through inhibition of MGMT expression and time-dependent inhibition of MDR1. EA combined with BEV may be an alternative treatment for drug-resistant gliomas.en_US
dc.language.isoengen_US
dc.publisherElsevier Science Incen_US
dc.identifier.doi10.1016/j.wneu.2019.08.257en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCancer therapyen_US
dc.subjectEllagic aciden_US
dc.subjectGlioblastomaen_US
dc.subjectTemozolomideen_US
dc.titleEllagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an in Vitro Glioblastoma Modelen_US
dc.typearticleen_US
dc.relation.journalWorld Neurosurgeryen_US
dc.departmentDBÜen_US
dc.identifier.volume132en_US
dc.identifier.startpageE59en_US
dc.identifier.endpageE65en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Cetin, Abdurrahman] Hlth Sci Univ, Dept Neurosurg, Gazi Yasargil Educ & Res Hosp, Diyarbakir, Turkey; [Biltekin, Burcu] Istanbul Atlas Univ, Med Fac, Dept Histol & Embryol, Istanbul, Turkey; [Degirmencioglu, Sevgin] Demiroglu Bilim Univ, Vocat Sch Hlth Serv, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster